Equity Profile

ELVN

Enliven Therapeutics, Inc.

Health CarePharmaceuticals$3.6B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as demand for new treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1-2026, Enliven reported an EPS of -$0.38, outperforming expectations by 13.64%. However, the stock fell by 2.21% the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with no analyst estimates available to guide sentiment. The stock's recent performance suggests uncertainty among investors.

Bull Case

If Enliven can report better-than-expected EPS and show signs of revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than anticipated or fails to provide clarity on its growth strategy, it could lead to a significant drop in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What insights can management provide on revenue growth and future guidance?

Understanding the company's growth trajectory is essential for assessing its long-term viability and potential stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Enliven's potential for a surprise in EPS due to recent improvements in operational efficiency.

Supporting Evidence

The company's history of beating EPS estimates 75% of the time suggests potential for positive surprises.

Options pricing indicates a significant expected move, reflecting uncertainty that could benefit the stock if results are favorable.

Key Risk

If the EPS comes in better than -$0.30, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve its financial performance amidst ongoing challenges in the pharmaceutical industry.

Bull Confirmed If

Reporting an EPS of -$0.30 or better, along with positive revenue growth, would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than -$0.50 would signal a bearish trend.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests the stock could rise by an average of 3.01%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 1.62%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments and their expected timelines.
2Management's commentary on cost management and operational efficiencies.
3Insights into market demand for Enliven's products.
4Guidance on future revenue expectations and growth strategies.
5Responses to questions about competitive pressures in the pharmaceutical sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1-2026, Enliven reported an EPS of -$0.38, outperforming expectations by 13.64%. However, the stock fell by 2.21% the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with no analyst estimates available to guide sentiment. The stock's recent performance suggests uncertainty among investors.

Bull Case

If Enliven can report better-than-expected EPS and show signs of revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than anticipated or fails to provide clarity on its growth strategy, it could lead to a significant drop in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What insights can management provide on revenue growth and future guidance?

Understanding the company's growth trajectory is essential for assessing its long-term viability and potential stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Enliven's potential for a surprise in EPS due to recent improvements in operational efficiency.

Supporting Evidence

The company's history of beating EPS estimates 75% of the time suggests potential for positive surprises.

Options pricing indicates a significant expected move, reflecting uncertainty that could benefit the stock if results are favorable.

Key Risk

If the EPS comes in better than -$0.30, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve its financial performance amidst ongoing challenges in the pharmaceutical industry.

Bull Confirmed If

Reporting an EPS of -$0.30 or better, along with positive revenue growth, would confirm a bullish outlook.

Bear Confirmed If

An EPS worse than -$0.50 would signal a bearish trend.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests the stock could rise by an average of 3.01%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 1.62%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments and their expected timelines.
2Management's commentary on cost management and operational efficiencies.
3Insights into market demand for Enliven's products.
4Guidance on future revenue expectations and growth strategies.
5Responses to questions about competitive pressures in the pharmaceutical sector.